Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611247 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
A Phase 2 study of Leukemia, Myeloid, sponsored by Bruno C. Medeiros.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT00611247 is a Phase 2 study of Leukemia, Myeloid that has completed, run by Bruno C. Medeiros. The registered enrollment target is 42 participants, below the 390-participant average among 8 other Leukemia, Myeloid trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00611247, a Phase 2 study of Leukemia, Myeloid, has completed, sponsored by Bruno C. Medeiros.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
Open-label, non-randomized, parallel assignment, phase 2 trial assessing the safety and efficacy of distinct temozolomide treatment regimens for patients with AML and poor prognosis
Conditions Studied
Interventions
- DRUG Temozolomide
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00611247
The ClinicalTrials.gov registry entry for NCT00611247 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 390-participant average among 8 other Leukemia, Myeloid trials with a reported enrollment target (89% lower). The listed sponsor is Bruno C. Medeiros, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Myeloid appearing as the primary indexed condition, and to 1 intervention - of which Temozolomide is the first listed.
NCT00611247 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00611247 about?
NCT00611247 is a clinical study titled "Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia". Open-label, non-randomized, parallel assignment, phase 2 trial assessing the safety and efficacy of distinct temozolomide treatment regimens for patients with AML and poor prognosis
What is the current status of trial NCT00611247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2007-12. Estimated completion is 2010-01.
What conditions does trial NCT00611247 study?
This clinical trial studies the following conditions: Leukemia, Myeloid.
What interventions are being tested in trial NCT00611247?
The interventions under investigation include: Temozolomide (DRUG).
Who is sponsoring clinical trial NCT00611247?
This trial is sponsored by Bruno C. Medeiros, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00611247 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myeloid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
-
Allo HSCT Using RIC and PTCy for Hematological Diseases
RECRUITING · Phase 2
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 1
-
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.